Vir Biotechnology Inc

We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and the cause of hundreds of billions of dollars of economic burden each year. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.

We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions.

We have an industry-leading management team, board of directors and scientific advisors with significant experience in immunology and infectious diseases, and with progressing product candidates from early stage research to clinical trials, regulatory approval and ultimately commercialization.

Guided by science, we relentlessly build on our immunologic expertise and technologies in pursuit of transformative medicines for infectious diseases. Our innovations stem from courage and bold ideas. We approach each day with a sense of optimism and humility

Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of the pathogen and the reasons previous approaches have failed. We then bring to bear a powerful set of technologies that we believe will, individually or in combination, lead to effective therapies. Our four current technologies are designed to stimulate and enhance the immune system. Antibody Platform - We have established a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. We engineer the fully-human antibodies that we discover to enhance their therapeutic potential. T Cell Platform - We are exploiting the unique immunology of human cytomegalovirus, or HCMV, a commonly occurring virus in humans, as a delivery vehicle – or vector – for vaccines to potentially treat and prevent infection by pathogens that are refractory to current vaccine technologies. HCMV is the most potent known inducer of T cell responses of any human virus and may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. In addition, we can make proprietary modifications in the HCMV genome that we expect will elicit different types of pathogen-appropriate T cell responses. We call this approach “immune programming,” and believe that this platform may also have applicability beyond infectious diseases, to areas such as cancer. Innate Immunity Platform - Moving beyond more traditional approaches that are used to evoke adaptive immunity or that directly target pathogens, where the development of resistance can occur, we plan to target host proteins as a means of creating host-directed therapies with high barriers to resistance. We believe that by leveraging the power of innate immunity, we can create medicines that break the “one-drug-for-one-bug” paradigm by producing one drug that has the properties needed to treat multiple bugs. siRNA Platform - We are harnessing the power of siRNA to inhibit pathogen replication, eliminate key host factors necessary for pathogen survival and remove microbial immune countermeasures.